Abstract:5519 Background: GRIM-19 is a novel gene associated with retinoid-interferon induced mortality (GRIM). The expression and function of GRIM-19 in SCCHN have not been reported to date. This study examined the expression of this gene and correlated it with the treatment outcomes in patients with locally advanced SCCHN. Methods: Thirty-nine baseline tumor tissues were collected from 54 patients who entered in a phase II study of induction chemotherapy with Paclitaxel, Ifosfamide, and Carboplatin (TIC) for locally advanced SCCHN. Immunohistochemistry analysis was performed for GRIM-19 expression using paraffin-embedded tumor specimens collected before the treatment. Weight index [WI = % Positive Staining (> 0) in tumor × Intensity Score, 0 - 300] was used for quantifying expression levels. Correlations between GRIM-19 expression and clinical characteristics were also evaluated. Results: The characteristics of the 39 patients are: median age: 58 years old; male 33/female 6; stage III 6/IV 33; tumor sites (Oral cavity 3, Oropharynx 21, Hypopharynx 5, Larynx 8, Others 2); differentiation (Grade I 7/ II 16/III16). With TIC chemotherapy for 3–4 cycles, 32/39 achieved CR/PR, and 7/39 had no change (NC) or progressive disease (PD). The positive staining of GRIM-19 was localized in both the cytoplasm and nuclei of the cancer cells. Ninety five percent of tumor samples (37/39) showed positive staining of GRIM-19 (WI/samples: 0/2; ∼ 100/12; ∼ 200/5; ∼300/20). The median value of GRIM-19 expression in the CR/PR group (WI: 187.5) was significantly lower than that in the NC/PD group (WI: 300) (p = 0.047). With a median follow-up of 56.9 months, the median survival of the low GRIM-19 expression group (WI ≤ 200, n = 19) has not been reached, while the median survival of the high GRIM-19 expression group (WI > 200, n = 20) was 39.9 months (p = 0.057). Conclusions: High expression of GRIM-19 correlated with poor clinical response and worsened survival for the TIC chemotherapy treatment in patients with locally advanced SCCHN. Therefore, it may serve as a good biomarker and deserves to be incorporated into future clinical trails. (Supported in part by 2RO1 CA75603 to D.M.S.). No significant financial relationships to disclose.

Upregulation of GRIM-19 Suppresses the Growth of Oral Squamous Cell Carcinoma in Vitro and in Vivo.

GRIM-19 Over-Expression Represses the Proliferation and Invasion of Orthotopically Implanted Hepatocarcinoma Tumors Associated with Downregulation of Stat3 Signaling.

Enhanced antitumor effect of cisplatin in human oral squamous cell carcinoma cells by tumor suppressor GRIM‑19.

Down-Regulation of Grim-19 Expression is Associated with Hyperactivation of Stat3-Induced Gene Expression and Tumor Growth in Human Cervical Cancers

Decreased Expression of Grim-19 by Dna Hypermethylation Promotes Aerobic Glycolysis and Cell Proliferation in Head and Neck Squamous Cell Carcinoma

Down-regulation of GRIM-19 is Associated with STAT3 Overexpression in Breast Carcinomas.

Grim-19 Repressed Hypoxia-Induced Invasion And Emt Of Colorectal Cancer By Repressing Autophagy Through Inactivation Of Stat3/Hif-1 Signaling Axis

GRIM-19 repressed hypoxia-induced invasion and EMT of colorectal cancer by repressing autophagy through inactivation of STAT3/HIF-1α signaling axis

Tumor suppressive protein gene associated with retinoid-interferon-induced mortality (GRIM)-19 inhibits src-induced oncogenic transformation at multiple levels

Downregulation of GRIM-19 promotes growth and migration of human glioma cells.

The Cell Death Regulator Grim-19 Is An Inhibitor Of Signal Transducer And Activator Of Transcription 3

Downregulation of Microrna 99a in Oral Squamous Cell Carcinomas Contributes to the Growth and Survival of Oral Cancer Cells.

Overexpression of GRIM-19, a mitochondrial respiratory chain complex I protein, suppresses hepatocellular carcinoma growth.

GRIM‑19‑mediated Stat3 activation is a determinant for resveratrol‑induced proliferation and cytotoxicity in cervical tumor‑derived cell lines.

Stat3 Inhibitor Wp1066 Attenuates Mirna-21 to Suppress Human Oral Squamous Cell Carcinoma Growth in Vitro and in Vivo

GRIM-19 Opposes Reprogramming of Glioblastoma Cell Metabolism Via HIF1α Destabilization.

GRIM-19 Expression and Its Correlation with Clinical Outcomes of an Induction Chemotherapy for Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)

miR-19a may function as a biomarker of oral squamous cell carcinoma (OSCC) by regulating the signaling pathway of miR-19a/GRK6/GPCRs/PKC in a Chinese population

GRIM-19 inhibition induced autophagy through activation of ERK and HIF-1α not STAT3 in Hela cells

Correlation Between GRIM- 19 and Its Target Gene Product STAT3 and Cervical Carcinoma

Effects of GRIM-19 on Growth of Cervical Cancer Cell Xenograft Tumor